Clinical predictors of inducible sustained ventricular tachycardia during electrophysiologic study in patients with chronic Chagas' heart disease

Abstract

BackgroundClinical independent predictors of inducible sustained ventricular tachycardia (VT) during electrophysiologic study (EPS) are not known in patients with chronic Chagas' heart disease. The purpose of this investigation was to fill this gap.MethodsThe medical charts of 47 patients with a positive serology for Chagas' disease who had undergone EPS between September 2006 and July 2012 at our institution were reviewed. Reasons for the EPS were the presence of unexplained syncope, non-sustained ventricular tachycardia (NSVT) on either resting ECG or 24 h-Holter monitoring as well as a LVEF < 55% and > 35% at echocardiography. A stepwise logistic regression analysis was performed to identify noninvasive predictors of inducible sustained VT/ventricular fibrillation during EPS.ResultsOn univariate analysis, syncopal episodes (p = 0.04), amiodarone therapy (p < 0.005), diastolic blood pressure (p = 0.03), creatinine serum levels (p < 0.001), potassium serum levels (p < 0.001), and lengthening of the QRS complex (p = 0.03) were associated with inducible sustained VT during EPS. In the multivariate model, amiodarone therapy (p = 0.03; hazard ratio = 10; Wald coefficient = 4.5; 95% confidence interval 1.2 to 85.2) was the only variable retained as independent predictor of inducible sustained VT during EPS.ConclusionAmiodarone therapy was the only independent variable associated with sustained VT inducibility during EPS in patients with chronic Chagas' heart disease.

The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

“…In fact, it has been associated with increased mortality in patients with Chagas cardiomyopathy with CHF in the more advanced forms of the syndrome, 21 and with inducible ventricular arrhythmias at Electrophysiologic Study. 55 Thus, amiodarone should be used with caution in patients with symptomatic ventricular arrhythmias in the stage C of CHF secondary to Chagas cardiomyopathy.…”

Association study between CCR2-CCR5 genes polymorphisms and chronic Chagas heart disease in Wichi and in admixed populations from Argentina

“…About one third of Trypanosoma cruzi chronically infected people will develop chronic Chagas cardiomyopathy (CCC). The clinical manifestations of CCC are ventricular arrhythmias, sudden cardiac death, chronic heart failure, thromboembolic phenomena and precordial chest pain [1]. The causes behind CCC development remain unclear; however, host, parasitic and environmental factors should be taken into account for a better understanding of the disease.…”

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population

“…Due to migration, it is estimated 750 000 infected carriers live in the USA or Europe. 531 , 532 VA, especially sustained VT is closely related to high mortality, sudden death (SCD) happening in 17–50% of chronically ill patients. 533 Based on the identification of different risk factors, Rassi et al .…”